dr. kahl on efficacy of targeted agents in relapsed/refractory indolent lymphomas
Published 4 years ago • 109 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:42
dr. kahl on adct-402 for relapsed/refractory b-cell non-hodgkin lymphoma
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
5:33
management of refractory follicular lymphoma
-
0:57
dr. kahl discusses unmet needs in mcl
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
4:30
follicular lymphoma relapsed/refractory disease
-
4:07
author voices: brad kahl, md
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll
-
1:25
targeted therapy for the treatment of follicular lymphoma
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
2:22
dr. yang on the efficacy of immunotherapy in follicular lymphoma
-
1:22
dr. jacobson on the safety profile of axi-cel in relapsed/refractory indolent lymphoma
-
6:15
therapy for relapsed follicular lymphoma
-
7:30
treating relapsed/refractory mantle cell lymphoma
-
24:44
novel therapeutic strategies in b cell lymphomas
-
0:50
dr. rosenthal on treatment strategies for indolent lymphomas